NFKB1 and glioma: Studies using the proteasome inhibitor bortezomib (PS-341), that also blocks NF-κB activation, have also demonstrated increased chemosensitivity of CRC cells to CPT-11 toxicity (16), and an increased cytotoxic effect of CPT-11 on glioma cells (52).